Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Receives Average Recommendation of “Buy” from Brokerages

Shares of Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) have earned a consensus rating of “Buy” from the six brokerages that are presently covering the company, Marketbeat.com reports. Six analysts have rated the stock with a buy rating. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $21.00.

ARTV has been the subject of several analyst reports. Needham & Company LLC reaffirmed a “buy” rating and set a $23.00 price objective on shares of Artiva Biotherapeutics in a research note on Wednesday, November 13th. HC Wainwright initiated coverage on Artiva Biotherapeutics in a research note on Monday, December 30th. They set a “buy” rating and a $20.00 price objective for the company.

Artiva Biotherapeutics Price Performance

ARTV opened at $3.77 on Tuesday. The business has a 50 day moving average price of $7.20 and a two-hundred day moving average price of $10.31. Artiva Biotherapeutics has a 52 week low of $3.37 and a 52 week high of $17.31.

Hedge Funds Weigh In On Artiva Biotherapeutics

A number of large investors have recently modified their holdings of ARTV. RA Capital Management L.P. purchased a new position in shares of Artiva Biotherapeutics during the 3rd quarter worth approximately $152,234,000. Franklin Resources Inc. purchased a new position in shares of Artiva Biotherapeutics during the 3rd quarter worth approximately $7,435,000. Geode Capital Management LLC purchased a new position in shares of Artiva Biotherapeutics during the 3rd quarter worth approximately $4,774,000. Samsara BioCapital LLC purchased a new position in shares of Artiva Biotherapeutics during the 3rd quarter worth approximately $4,506,000. Finally, Wellington Management Group LLP purchased a new position in shares of Artiva Biotherapeutics during the 3rd quarter worth approximately $2,912,000.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.